


PRODUCT: Lopinavir**ALTERNATE NAME:** (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide**CATALOG #:** 2241-50, 250**AMOUNT:** 50 mg, 250 mg**STRUCTURE:****MOLECULAR FORMULA:** C₃₇H₄₈N₄O₅**MOLECULAR WEIGHT:** 628.81**CAS NUMBER:** 192725-17-0**APPEARANCE:** White to off-white solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** At -20° C. Protect from light and moisture**DESCRIPTION:** A protease inhibitor with high specificity for HIV-1 protease. Inhibition of HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation. It has been reported to reduce morbidity and mortality in a retrospective cohort study of SARS-CoV-2 infection and to reduce lung pathology in non-human primates. It was not associated with reduced viral replication or improved clinical outcome in an open-label randomized clinical trial in patients with COVID-19.**RELATED PRODUCTS:**Acyclovir (**Cat. No. 2200-50, 250**)Ganciclovir (**Cat. No. 1918-50, 250, 1000**)Ribavirin (**Cat. No. 2199-10, 50**)Tenofovir disoproxil fumarate (**Cat. No. 1920-5, 25**)Valacyclovir hydrochloride hydrate (**Cat. No. 2201-10, 50**)**USAGE: FOR RESEARCH CH USE ONLY! Not to be used in humans**

